Accelerating Manufacturing for Next Generation hiPSC-Based Clinical Therapies
Summary: During this session, we review progress in several areas of advanced development and their impact on readiness for large scale manufacturing.
The Post-COVID Supply Chain
Summary: During this panel discussion, executives share how their companies adapted to the challenges and what lessons they will take forward to ensure…
Catalent’s Chair and CEO Shares His Views About Drug Development and Manufacturing in a Pandemic
Summary: In December 2021, John Chiminski was featured on the expert panel of STAT’s “A Look Ahead at Biotech in 2022” event, which focused on the ongoing battle against the SARS-CoV-2 virus and explored what might be in store for the biotech industry in the years to come.
mRNA-A 20 Year Voyage to Patients
Summary: On December 13, 2021, EuropaBio hosted the final event of its 25th Anniversary programme with a focus on the story of mRNA.
Our predictions for the biopharma industry in 2022
Catalent’s CEO John Chiminski & Endpoints News’ John Carroll discuss their predictions for what 2022 has in store for the biopharma industry.